Active substance
Results for the substance ponatinib
3 results
About this active substance
Ponatinib is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with the T315I mutation. It works by blocking the activity of abnormal proteins that drive cancer cell growth.
The medication is taken orally, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects and potential side effects.
Patients should be aware of potential side effects, such as hypertension, skin rashes, or thrombosis. It is important to inform the doctor of any unusual symptoms.
Common side effects include hypertension, skin rashes, and fatigue. In rare cases, severe reactions such as heart failure, arterial thrombosis, or pancreatitis may occur. Patients should be informed of these risks before use.
The medication is taken orally, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects and potential side effects.
Patients should be aware of potential side effects, such as hypertension, skin rashes, or thrombosis. It is important to inform the doctor of any unusual symptoms.
Common side effects include hypertension, skin rashes, and fatigue. In rare cases, severe reactions such as heart failure, arterial thrombosis, or pancreatitis may occur. Patients should be informed of these risks before use.
-
-
ICLUSIG 45mg film-coated tablets INCYTE BIOSCIENCES ORIGINAL MEDICINE
-
ICLUSIG 30mg film-coated tablets INCYTE BIOSCIENCES ORIGINAL MEDICINE